Colgate-Palmolive

CL

Market cap $72B

CL's innovation strategy is driving market share gains as premium launches, pricing and science-based products support growth across oral care and pet nutrition.

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

Colgate-Palmolive (NYSE:CL | CL Price Prediction) is exactly the kind of name investors hunt for when the macro picture gets murky.

Investors interested in stocks from the Consumer Products - Staples sector have probably already heard of Ollie's Bargain Outlet (OLLI) and Colgate-Palmolive (CL). But which of these two companies is the best option for those looking for undervalued stocks?

PG's U.S. Baby Care slump remains a weak spot, but strong global growth and targeted investments suggest it is a fixable issue, not a long-term drag.

Colgate-Palmolive delivered 8% sales growth in Q1 2026, but EPS declined 6%, warranting a conservative hold rating. I see organic growth of just 2.9%, with North America sales falling due to increased toothpaste competition and margin compression. FX tailwinds drove significant growth in Latin America, EMEA, and APAC, raising concerns about sustainability if currency trends reverse.

Companies like Procter & Gamble and Colgate-Palmolive have embedded themselves so deeply into daily habits that buying their products stops feeling like a decision at all. Their growth narratives are less about convincing people to switch and more about scaling trust and upgrading within it.

Colgate-Palmolive (NYSE:CL | CL Price Prediction) stock picked up a fresh price target raise from JPMorgan on Monday, May 4, with the firm lifting its target to $96 from $95 while maintaining its Overweight rating.

Colgate-Palmolive remains a Buy, supported by resilient fundamentals, an attractive and still sustainable dividend yield while they hold the Dividend King status, and prudent valuation amid macro and geopolitical headwinds. CL posted solid Q1 results, with 8.4% net sales growth, robust free cash flow, and reaffirmed 2026 sales and EPS growth guidance despite Iran-driven margin pressures. Rising input and logistics costs, driven by the Iran conflict, are expected to pressure gross margins, but CL's strong cash flows support ongoing shareholder returns.

CL beats Q1 earnings estimates as pricing and volume lift sales 8.4%; costs and SGPP charges weigh on margins, but outlook stays intact.